succinylcholine, 200 mg/10 mL, (20 mg/mL), 10 mL syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6011-2
Published August 9, 2023 · Recall initiated: July 17, 2023
Summary
FDA records drug Class II recall D-1056-2023, published August 9, 2023 and initiated July 17, 2023. Recalling firm: Central Admixture Pharmacy Services Inc; Status: Terminated; Reported quantity: 12,239 syringes; Lot: Lot: 17-270532, 17-270538, Exp, 7/16/2023; 17-270601, Exp, 7/17/2023; 17-270888, Exp, 7/20/2023; 17-271680, Exp, 8/2/2023; 17-271828, Exp, 8/6/2023; 17-271959, Exp, 8/8/2023; 17-272232, 17-272239, Exp, 8/13/2023; 17-272338, Exp, 8/15/2023; 17-272452, 17-272463, Exp, 8/16/2023; 17-272551, 17-272557, Exp, 8/17/2023; 17-272800, 17-272819, Exp, 8/22/2023; 17-272889, 17-272917, Exp, 8/23/2023; 17-272978, Exp, 8/24/2023; 17-273077, Exp, 8/28/2023; 17-273166, Exp, 8/29/2023; 17-273604, Exp, 9/5/2023; 17-273729, 17-273731, Exp, 9/6/2023; 17-273854, 17-273870, Exp, 9/10/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of assurance of sterility: Lack of validation data for sanitization cycles
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Distributor
- Nationwide in the USA
- Lot
- Lot: 17-270532, 17-270538, Exp, 7/16/2023; 17-270601, Exp, 7/17/2023; 17-270888, Exp, 7/20/2023; 17-271680, Exp, 8/2/2023; 17-271828, Exp, 8/6/2023; 17-271959, Exp, 8/8/2023; 17-272232, 17-272239, Exp, 8/13/2023; 17-272338, Exp, 8/15/2023; 17-272452, 17-272463, Exp, 8/16/2023; 17-272551, 17-272557, Exp, 8/17/2023; 17-272800, 17-272819, Exp, 8/22/2023; 17-272889, 17-272917, Exp, 8/23/2023; 17-272978, Exp, 8/24/2023; 17-273077, Exp, 8/28/2023; 17-273166, Exp, 8/29/2023; 17-273604, Exp, 9/5/2023; 17-273729, 17-273731, Exp, 9/6/2023; 17-273854, 17-273870, Exp, 9/10/2023;
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDATotal Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, (patient specific), Compound Volume 416.8 mLAugust 12, 2026
- FDAHYDROmorphone in 0.9% sodium chloride, 6 mg/30 mL, (0.2 mg/mL), 30 mL Syringe, Rx only, CAPS, CentralOctober 11, 2023
- FDAfentaNYL, 5,000 mcg/100 mL, (50 mcg/mL), 100 mL Bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935October 11, 2023
- FDAfentaNYL, 100 mcg/2 mL, (50 mcg/mL), 3 mL Syringe, Rx only, Repackaged by CAPS Inc., 7935 Dunbrook Road, SuiteOctober 11, 2023
- FDAHYDROmorphone in 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 50 mL Syringe, Rx only, Central AdmixtureAugust 9, 2023
- FDAHYDROmorphone in Dextrose 5%, 0.5 mg/5 mL (0.1 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road,August 9, 2023
Questions about this recall
Was succinylcholine, 200 mg/10 mL, (20 mg/mL), 10 mL syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6011-2 recalled?
Yes. FDA published recall D-1056-2023 on August 9, 2023. Reported hazard: Lack of assurance of sterility: Lack of validation data for sanitization cycles
What should I do if I have this product?
Voluntary: Firm initiated · Letter